Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT02660528
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This proposed study sets out to examine the antidepressant effects of tocilizumab among patients with treatment-refractory major depression.

Key Dates

Start date
Apr 30, 2016
Status verified
Oct 2020
Primary completion
Jun 30, 2020
Completion
Jun 30, 2020

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tocilizumab
    Tocilizumab 162 mg sc q2weeks x 4 doses

Primary Outcome Measure

Absolute Change on Hamilton Depression Rating Scale (HDRS) [ Time Frame: Baseline to 8 Weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02115-

Find similar trials in Boston, MA

By condition
Depression
By specialty
PsychiatryMental healthBehavioral health
By research site
Brigham and Women's Hospital· Boston, MA

Related Studies